PAH

Pharma

Merck preps filings after Winrevair succeeds in severe PAH study

Eight months after snaring a first FDA green light, Merck & Co. is bolstering the case for the chief asset in its $11.5 billion Acceleron acquisition.

Fraiser Kansteiner Nov 25, 2024 9:00am

FDA approves Johnson & Johnson's combo pill Opsynvi for PAH

Mar 25, 2024 11:05am

FDA faces lawsuit from United on its Liquidia review process

Feb 21, 2024 2:31pm

Janssen rounds out final live talk of 2022 for PH nurses

Dec 7, 2022 10:31am

EMA examines key Actelion med Uptravi following 5 patient deaths in France

Feb 14, 2017 10:50am

Can Adempas meet Bayer's growth expectations after a canceled trial?

May 17, 2016 7:36am